Drug Type Autologous CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism AGRE2 inhibitors(adhesion G protein-coupled receptor E2 inhibitors), CLL-1 inhibitors(C-Type lectin domain family 12 member A inhibitors), Immunologic cytotoxicity + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapsing acute myeloid leukemia | Phase 1 | United States | 18 Apr 2024 |